Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Hiller

Pain Medicine San Diego, CA Medical Doctor

NPI 1275739674 CMS profile 1197365

15004 Innovation Dr, San Diego, CA 92128

Open in the dashboard

General payments

$29,816

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Hiller of San Diego, CA is reported in the CMS Open Payments database as having received $29,816 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,739 61
2024 General $8,684 29
2023 General $2,453 30
2022 General $195 7
2021 General $462 15
2020 General $96 7
2019 General $1,186 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Hiller
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to David Hiller were reported at $16,739. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year David Hiller Pain Medicine median Middle half National median
2019 $1,186 $498 $126–$1,682 $163
2020 $96 $284 $80–$910 $114
2021 $462 $399 $112–$1,219 $132
2022 $195 $455 $137–$1,484 $149
2023 $2,453 $484 $128–$1,495 $160
2024 $8,684 $498 $131–$1,540 $164
2025 $16,739 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $17,580 69 payments
  2. SPR Therapeutics, Inc $9,208 20 payments
  3. Abbott Laboratories $1,548 55 payments
  4. Avanos Medical $321 2 payments
  5. Globus Medical, Inc. $232 3 payments
  6. Pacira Pharmaceuticals Incorporated $225 1 payment
  7. Stimwave Technologies Incorporated $194 2 payments
  8. Boston Scientific Corporation $135 2 payments
  9. BIOTRONIK NRO, Inc. $102 2 payments
  10. Relievant Medsystems, Inc. $89 1 payment
  11. Other $183 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,350 11 payments
  2. Travel and Lodging $5,080 21 payments
  3. Food and Beverage $4,161 134 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $225 1 payment
Products named General payments · program years 2019–2025
  1. Evoke $15,340 54 payments
  2. SPRINT PNS System $9,208 20 payments
  3. Evoke SCS $2,240 15 payments
  4. Proclaim Family of SCS IPGs $825 19 payments
  5. Proclaim IPG $323 10 payments
  6. COOLIEF COOLED RADIOFREQUENCY $297 1 payment
  7. Senza $232 3 payments
  8. EXPAREL $225 1 payment
  9. PROCLAIM $134 8 payments
  10. Intracept $110 1 payment
  11. Other $880 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$316,607

Of which drugs: $11,211

Medicare patients

731

Average age 76

Services billed

17,036

427 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Ischemic heart disease 28%
Chronic kidney disease 26%
Osteoporosis 26%
Depression 25%
Atrial fibrillation 21%
Diabetes 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 11 37 $3,397
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 101 440 $2,434
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 145 1,244 $956
Injection, methylprednisolone acetate, 1 mg J1010 Office 153 8,324 $858
Injection, methylprednisolone acetate, 40 mg J1030 Office 68 81 $388
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 314 1,902 $198
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 77 920 $83
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 17 333 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record